These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31489688)

  • 1. Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.
    Tu S; Huang R; Guo Z; Deng L; Song C; Zhou X; Yue C; Zhang L; He Y; Yang J; Liang Z; Du J; Cao P; Li Y; Chang LJ; Li Y
    Am J Hematol; 2019 Dec; 94(12):E322-E325. PubMed ID: 31489688
    [No Abstract]   [Full Text] [Related]  

  • 2. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
    Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
    Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
    Wang S; Wang X; Ye C; Cheng H; Shi M; Chen W; Qi K; Wang G; Wu Q; Zeng L; Li Z; Jing G; Zheng J; Xu K; Cao J
    Am J Hematol; 2021 May; 96(5):E162-E165. PubMed ID: 33580974
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
    Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia.
    Perica K; Flynn J; Curran KJ; Rivere I; Wang X; Senechal B; Halton E; Diamonte C; Pineda J; Bernal Y; Gonen M; Sadelain M; Brentjens RJ; Park JH
    Leukemia; 2021 Nov; 35(11):3268-3271. PubMed ID: 33686196
    [No Abstract]   [Full Text] [Related]  

  • 7. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
    Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy.
    Ragoonanan D; Tambaro FP; Khazal SJ; Tewari P; Petropoulos D; Champlin R; Mahadeo KM
    Pediatr Blood Cancer; 2021 May; 68(5):e28839. PubMed ID: 33258192
    [No Abstract]   [Full Text] [Related]  

  • 12. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
    Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
    Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.
    Aldoss I; Khaled SK; Budde E; Stein AS
    Curr Oncol Rep; 2019 Jan; 21(1):4. PubMed ID: 30666425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.
    Hu Y; Sun J; Wu Z; Yu J; Cui Q; Pu C; Liang B; Luo Y; Shi J; Jin A; Xiao L; Huang H
    J Hematol Oncol; 2016 Aug; 9(1):70. PubMed ID: 27526682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
    Thomas X; Paubelle E
    Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical Care Management of Chimeric Antigen Receptor T Cell-related Toxicity. Be Aware and Prepared.
    Azoulay E; Shimabukuro-Vornhagen A; Darmon M; von Bergwelt-Baildon M
    Am J Respir Crit Care Med; 2019 Jul; 200(1):20-23. PubMed ID: 30676776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.